source
- Rapport Therapeutics says it is ready to launch its seizure drug independentlyIn a recent interview, CEO Abe Ceesay explained that Rapport Therapeutics has assembled an investor syndicate and feels fully prepared to bring its seizure drug to market on its own. Founded in 20…
- J&J reports positive Phase 2/3 results for Imaavy in rare autoimmune anemia, paving way for label expansionJohnson & Johnson announced that its drug Imaavy, already approved for myasthenia gravis, produced durable hemoglobin improvements in a Phase 2/3 trial for warm autoimmune hemolytic anemia, a rare…